Simoa® N4PD Advantage PLUS is a digital immunoassay for the quantitative determination of BD-Tau, NfL, BD-Tau, GFAP*, and UCH-L1* concentrations in human serum, EDTA plasma, and CSF samples.
(For detailed specifications, please refer to the N4PD Advantage PLUS Datasheet)
The assay kit includes all necessary reagents and controls to perform 96 tests.
Uncover Insights with BD-Tau and Key Neurology Biomarkers
BD-Tau as a Plasma Biomarker of Neurodegeneration in Alzheimer’s Disease
Realizing the promise of multimodal diagnostics raises important questions: How should we think about integrating these different sources of information? Where can multimodal approaches add the most value? And what…
Disease is complex, dynamic, and heterogeneous, and no one biomarker modality can capture every dimension of that complexity. Liquid and tissue biomarkers answer different biological questions, each providing a distinct…
Cancer
Lung cancer is a formidable foe. Globally, it is the leading cause of cancer-related deaths in men and women, with non-small lung cancer (NSCLC) representing more than 80% of all…
The promise of proteomics lies in its ability to illuminate disease biology at scale, transform translational research, and guide the development of precision diagnostics and targeted therapies. While genomic technologies…
Translating proteomic discovery into clinical action requires more than scale, it demands precision, reproducibility, and quantitative clarity. The Quanterix Simoa® digital immunoassay technology was purpose-built to meet the demands of…
Alzheimer’s disease (AD) is increasingly understood as a multifaceted disorder involving not only amyloid and tau pathology, but also significant contributions from neuroinflammation and vascular dysfunction. In particular, astrocyte reactivity…
Neurology
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Neurology
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…
Molecular Barcoding Kit Now Available Globally; TIME and high-plex ADC panels confirmed for Q4 shipment; Accelerator Laboratory Services open custom ADC panel development BILLERICA, Mass.–September 25, 2026–Quanterix Corporation (NASDAQ: QTRX)…
BILLERICA, Mass.–September 14, 2026–Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of…
Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends date for attaining…
Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences BILLERICA, Mass.–August 10, 2026–Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker…
BILLERICA, Mass. – August 6, 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital…
BILLERICA, Mass. – August 4 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August…
BILLERICA, Mass. – June 16, 2026 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15,…
Explore our library of resources, posts and materials.
Contact our team for customer support, distributor inquiries, or general questions.
